doxorubicin and its epimerized analog epirubicin were tested at a dose of 75 mg/m2 given iv every 3 weeks to 42 patients with advanced breast cancer , 23 of whom were in relapse from prior cyclophosphamide , methotrexate , and 5-fu ( cmf ) chemotherapy .
C0025677
methotrexate
C0950521
cmf